Targeting TL1A/DR3 Signaling Offers a Therapeutic Advantage to Neutralizing IL13/IL4Rα in Muco-Secretory Fibrotic Disorders

Targeting TL1A/DR3 Signaling Offers a Therapeutic Advantage to Neutralizing IL13/IL4Rα in Muco-Secretory Fibrotic Disorders

Mucus secretion is an important feature of asthma that highly correlates with morbidity. Current therapies, including administration of mucolytics and anti-inflammatory drugs, show limited effectiveness and durability, underscoring the need for novel effective and longer lasting therapeutic approach...

Full description

Bibliographic Details
Main Authors: Hope Steele, Kacey Sachen, Andrew J. McKnight, Rachel Soloff, Rana Herro
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
mucus
asthma
TL1A
IL13
fibrosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.692127/full

Similar Items

Similar Items